Merck Terns Acquisition $6.7B Surge as Keytruda Cliff Nears
Can the Merck Terns Acquisition really plug the looming Keytruda revenue gap or is $6.7 billion just a high-risk oncology bet? Maik Kemper Editor in…
BioNTech Leadership Change: -17.9% Crash After Billion-Euro Loss
Can BioNTech’s surprise leadership change and deepening losses turn a Covid-era star into a long-term oncology value play or a value trap? How did markets…